| Identification | Back Directory | [Name]
1,3-Propanediol, 2-amino-2-[2-[4'-(2-propyl-4-oxazolyl)[1,1'-biphenyl]-4-yl]ethyl]- | [CAS]
1418093-75-0 | [Synonyms]
IMMH001
1,3-Propanediol, 2-amino-2-[2-[4'-(2-propyl-4-oxazolyl)[1,1'-biphenyl]-4-yl]ethyl]- | [Molecular Formula]
C23H28N2O3 | [MOL File]
1418093-75-0.mol | [Molecular Weight]
380.48 |
| Chemical Properties | Back Directory | [Boiling point ]
618.6±55.0 °C(Predicted) | [density ]
1.165±0.06 g/cm3(Predicted) | [form ]
Solid | [pka]
12.19±0.20(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
IMMH001, also called SYL930, is an orally active, potent and selective S1P1 (sphingosine-1-phosphate receptor 1) agonist. IMMH001 decreased levels of both chemokines and proinflammatory cytokines, including IL-1β, IL-5, IL-18, IP10, CCL3, and CCL5. IMMH001 can be used for rheumatoid arthritis (RA) research[1][2]. | [in vivo]
IMMH001 is converted to the active form, its monophosphate ester (S)-IMMH001-P, by sphingosine kinase 1 (SphK1) and sphingosine kinase 2 (SphK2) in vivo[1].
IMMH001 suppresses both Th1 cell (IL-1β, IL-18, and IP10) and Th2 cell (IL-5)-mediated disease reactions in damaged joints[2].
IMMH001 (0.3-2.4 mg/kg, Orally; twice a week, for 28 days, AA rats; for 30 days, CIA rats) relieves the damage of AA (adjuvant-induced arthritis) and CIA (collagen-induced arthritis) rats’ joints[2]. | [IC 50]
S1PR1 | [References]
[1] Xiao Q, et al. Design and synthesis of analogues of the sphingosine-1-phosphate receptor 1 agonist IMMH001 with improved phosphorylation rate in human blood. Bioorg Med Chem. 2020 Nov 1;28(21):115722. DOI:10.1016/j.bmc.2020.115722
[2] Jin J, et al. Sphingosine-1-Phosphate Receptor Subtype 1 (S1P1) Modulator IMMH001 Regulates Adjuvant- and Collagen-Induced Arthritis. Front Pharmacol. 2019 Sep 19;10:1085. DOI:10.3389/fphar.2019.01085 |
|
|